Zydus Lifesciences gets USFDA nod for generic medication, Health News, ET HealthWorld

[Pelican Press 0]

This is the hidden content, please

• Sign In
• or
• Sign Up

Zydus Lifesciences gets USFDA nod for generic medication, Health News, ET HealthWorld

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

New Delhi: Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to market a generic medication to treat Parkinson’s ********. The company has received approval from the US Food and ***** Administration (USFDA) to market Amantadine extended-release capsules (68.5 mg) and tentative approval for Gocovri (137 mg) capsules, the ***** firm said in a statement.

Amantadine extended-release capsules are indicated for the treatment of dyskinesia in patients with Parkinson’s ********.

The ***** will be manufactured at the group’s formulation manufacturing facility in Ahmedabad SEZ – II, Zydus Lifesciences said.

“This approval makes Zydus eligible for 180 days of exclusivity for Amantadine extended-release capsules (68.5 mg), it added.

The Gujarat-based group said it now has 400 approvals from the USFDA.

• Published On Aug 28, 2024 at 05:55 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

Download ETHealthworld App

• Get Realtime updates
• Save your favourite articles

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

Scan to download App
data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

This is the hidden content, please

• Sign In
• or
• Sign Up

#Zydus #Lifesciences #USFDA #nod #generic #medication #Health #News #HealthWorld

This is the hidden content, please

• Sign In
• or
• Sign Up

This is the hidden content, please

• Sign In
• or
• Sign Up